Monroe Capital backs therapeutic products company

The $20 million loan will aid in the growth of the private equity sponsored Cytovance Biologics.

Chicago-based lender Monroe Capital has arranged a $20 million senior secured credit facility for Cytovance Biologics, to assist in the growth of the company which private equity sponsor Great Point Partners is working on. Monroe acted as the sole lead arranger and administrative agent in the debt transaction, Monore announced today (28 October).


Based in Oklahoma City, Oklahoma, Cytovance is a contract manufacturing organization of mammalian and microbial biologics. The company works with biotechnology and pharmaceutical companies in the development and manufacturing of proteins, antibodies, and cell-based therapeutic products. Cytovance supports its customers from clinical development to commercial launch in domestic and international markets.


Monroe Capital is a provider of senior and junior debt and equity co-investments to mid-market companies in the US and Canada. Investment types include unitranche financings, cash flow and enterprise value based loans, acquisition facilities, mezzanine debt, second lien or last-out loans and equity co-investments.